Study Summary
This trial will test a combination of therapies for stage IB-III non-small cell lung cancer. If successful, it could become a new standard of care for this disease.
- Non-Small Cell Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: From beginning of study treatment to approximately day 49-63 on study.
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Protocol Therapy
1 of 1
Experimental Treatment
25 Total Participants · 1 Treatment Group
Primary Treatment: SBRT · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 15 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many people are being asked to participate in this clinical trial?
"That is correct. As of February 22nd, 2022, this clinical trial was still recruiting patients that had first been posted about on October 5th, 2021. They are seeking 25 individuals from 1 medical location." - Anonymous Online Contributor
What is the history of Ipilimumab in research?
"Ipilimumab is being researched in 796 clinical trials, 86 of which are currently active. The many Phase 3 studies for Ipilimumab primarily take place in Pittsburgh, Pennsylvania; however, there are 43300 locations running these sorts of trials." - Anonymous Online Contributor
What are the conditions Ipilimumab is used to treat?
"Treatments that can be administered using Ipilimumab include anti-angiogenic therapy, malignant neoplasms, and unresectable melanoma." - Anonymous Online Contributor
Are volunteers still being sought for this experiment?
"Based on the information available on clinicaltrials.gov, it appears that this study is still recruiting patients. The trial was first posted on 10/5/2021 and was last updated on 2/22/2022. They are looking for a total of 25 participants from 1 site." - Anonymous Online Contributor
Could you explain the possible risks associated with Ipilimumab?
"While there is data supporting Ipilimumab's safety, it garnered a score of 2 because there is no evidence backing its efficacy." - Anonymous Online Contributor